Marco Davila

Oncology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 112 publications

Early-Onset Hemophagocytic Lymphohistiocytosis and Inflammatory Neurotoxicity Prior to Post-transplant Cyclophosphamide: A Report of Two Cases.

Early-Onset Hemophagocytic Lymphohistiocytosis and Inflammatory Neurotoxicity Prior to Post-transplant Cyclophosphamide: A Report of Two Cases.

Journal: Cureus

Published: July 14, 2026

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.

Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma.

Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma.

Journal: JCO clinical cancer informatics

Published: March 20, 2026

System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.

System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.

Journal: Transplantation and cellular therapy

Published: March 12, 2026

Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel.

Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel.

Journal: Journal of the neurological sciences

Published: December 11, 2025

Analysis of epidemiologic factors and treatment effects on immunophenotypes in hematologic malignancy patients.

Analysis of epidemiologic factors and treatment effects on immunophenotypes in hematologic malignancy patients.

Journal: Leukemia & lymphoma

Published: November 13, 2025

Cre-dependent gene expression enables thymic development of autoreactive tumor-associated antigen targeting CAR-T cells.

Cre-dependent gene expression enables thymic development of autoreactive tumor-associated antigen targeting CAR-T cells.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: September 07, 2025

Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.

Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.

Journal: Leukemia

Published: August 18, 2025

Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies.

Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies.

Journal: Transplantation and cellular therapy

Published: August 01, 2025

CD28 co-stimulatory domain enhances efficacy of CER T cell therapy compared to 4-1BB in an ovarian cancer mouse model.

CD28 co-stimulatory domain enhances efficacy of CER T cell therapy compared to 4-1BB in an ovarian cancer mouse model.

Journal: Scientific reports

Published: July 21, 2025

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing.

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing.

Journal: Journal for immunotherapy of cancer

Published: July 04, 2025

Showing 1-12 of 112

Last Updated: 09/26/2026